Your session is about to expire
← Back to Search
Antiretroviral Therapy for ALS
Study Summary
This trial is testing whether drugs used to treat HIV can suppress a virus found in some people with ALS.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2011 Phase 4 trial • 25 Patients • NCT01232127Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- A specific ratio of HERV-K to RPP measured by a test at the screening visit is greater than or equal to 13.You have had a positive test for HIV or HTLV-1 in the past.You have been diagnosed with ALS by a neurologist with special training in nerve and muscle conditions, using specific criteria set by a global neurology organization.You rely on a breathing machine during the day for assistance with breathing.You have had a serious allergic reaction to sulfonamide medications.You have been diagnosed with the disease for less than 2 years, or if it's been longer, your disease has been getting worse slowly enough for you to finish the study.Your liver, kidney, blood clotting, and blood cell levels are too high or too low. You also have positive tests for hepatitis B or C.
- Group 1: ALS
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are enrollees currently being accepted for this research endeavor?
"Affirmative, the online record for this medical trial on clinicaltrials.gov indicates that it is actively recruiting participants as of November 16th 2022. This study was first posted in April 1st 2019 and requires 200 volunteers from 2 different sites."
Is Ritonavir a safe treatment option for individuals?
"The safety of Ritonavir was judged to be a 1 on our team's scale due to the scarcity of data from Phase 1 trials, which offer minimal insight into efficacy and security."
To what ailments does Ritonavir deliver relief?
"Ritonavir is a highly effective medication for treating virologically suppressed conditions over 3 months. It has also proven to be beneficial in other medical contexts, such as tenofovir treatment failure and compensated liver disease."
Could you elucidate other investigations that have focused on Ritonavir?
"At the moment, 112 studies are examining Ritonavir where 34 of them have reached phase 3. The trials for this specific immunomodulator are available at various medical centres across 2320 locations in Miami and beyond."
How many individuals are currently participating in this clinical research?
"Affirmative. The information available on clinicaltrials.gov demonstrates that this experiment is presently recruiting participants, which were first listed on April 1st 2019 and modified lastly in November 16th 2022. Two sites are taking part in the research where 200 subjects need to be enrolled."
Share this study with friends
Copy Link
Messenger